Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms ( e.g. , glomerular hyperfiltration, inflammation, and fibrosis). Additionally, greater attention to dissemination and implementation of best practices is needed in both clinical and community settings.Introduction
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pathogenesis of DKD involves a complex interplay of hyperglycaemia-induced metabolic alterations, haemodynamic changes and various types of intracellular stress.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic kidney disease (DKD) is one of the most common and life-threatening diabetic complications and a leading cause of CKD and kidney failure worldwide126.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Collectively, these processes induce the production of a range of cytokines, chemokines and growth factors that promote cell injury, inflammation and kidney fibrosis.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A plausible mechanistic explanation for the renoprotective effect of SGLT2 inhibitors is correction of aberrant glomerular haemodynamics induced by hyperglycaemia, which drive progressive nephron loss.34,35”
From SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Even with current therapies available [6–10], patients with T2DM and chronic kidney disease (CKD) still experience a significant cardiovascular and renal morbidity and mortality.”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Trends in Obesity Among Adults in the United States, 2005 to 2014
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016) · JAMA · doi:10.1001/jama.2016.6458 · Cited by 2,803
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749 · cited 8×
“Hyperglycemia In normoalbuminuric patients with DM1, poor glycemic control is an independent predictor of progression to development of proteinuria (albuminuria) and/or ESRD (14).”
InfluentialPathologic Classification of Diabetic Nephropathy
Tervaert, T. W. C., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010010 · Cited by 1,690
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Kidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Self-citationCombined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153 · cited 4×
“The preferred test for albuminuria is a urinary albumin-to-creatinine ratio performed on a spot sample, preferably in the morning (51,52).”
InfluentialSelf-citationGlobal status report on noncommunicable diseases
Chan, M. (2010) · Cited by 1,065
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036 · cited 1×
“The increasing prevalence of DKD parallels the dramatic worldwide rise in prevalence of diabetes (4,5).”
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016) · JAMA · doi:10.1001/jama.2016.10924 · Cited by 1,026
Self-citationThe Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy
Mogensen, C. E., Christensen, C. K., & Vittinghus, E. (1983) · Diabetes · doi:10.2337/diab.32.2.s64 · Cited by 967
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Self-citationBakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
Bakris, G. L. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1555 · Cited by 469
Histopathology of Diabetic Nephropathy
Fioretto, P., & Mauer, M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.012 · Cited by 467 · cited 2×
“Mesangial volume expansion is detectable within 5–7 years after DM1 diagnosis (14,25,27,28).”
Pohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110919 · Cited by 375 · cited 2×
“140mmHg in patients with DM2 has been associated with higher risk of ESRD and death (23,24).”
Epidemiology of Diabetic Kidney Disease
Reutens, A. T. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.001 · Cited by 326 · cited 1×
“This microvascular complication develops in approximately 30% of patients with type 1 diabetes mellitus (DM1) and approximately 40% of patients with type 2 diabetes mellitus (DM2) (2,3).”
The Early Natural History of Nephropathy in Type 1 Diabetes
Drummond, K., Mauer, M., & for the International Diabetic Nephropathy Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1580 · Cited by 303
de Zeeuw, D., Coll, B., Andress, D., Brennan, J. J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H. J., Makino, H., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080830 · Cited by 302
The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Tuttle, K. R., Bakris, G. L., Toto, R. D., McGill, J. B., Hu, K., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2686 · Cited by 300
Self-citationEffect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Leibowitz, G., Bhatt, D. L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0621 · Cited by 268
Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2322 · Cited by 240
Gaede, P. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh470 · Cited by 223
Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M., Chahin, J., Méndez, M. L., Gallego, E., Macía, M., del Castillo, N., Rivero, A., Getino, M. A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010012 · Cited by 221
Tuttle, K. R., Bruton, J. L., Perusek, M. C., Lancaster, J. L., Kopp, D. T., & DeFronzo, R. A. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106063242304 · Cited by 217
Self-citationPapademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
Bilous, R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02496.x · Cited by 174
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms
Tonna, S. J., El‐Osta, A., Cooper, M. E., & Tikellis, C. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.55 · Cited by 167
The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007
Fioretto, P., Caramori, M. L., & Mauer, M. S. (2008) · Diabetologia · doi:10.1007/s00125-008-1051-7 · Cited by 157
An autopsy study suggests that diabetic nephropathy is underdiagnosed
Klessens, C. Q. F., Woutman, T. D., Veraar, K., Zandbergen, M., Valk, E. J. J., Rotmans, J. I., Wolterbeek, R., BRUIJN, J. A., & Bajema, I. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.01.023 · Cited by 145
JAK inhibition in the treatment of diabetic kidney disease
Brosius, F. C., Tuttle, K. R., & Kretzler, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4021-5 · Cited by 140
Self-citationon behalf of the PERL Consortium, Maahs, D. M., Caramori, L., Cherney, D. Z. I., Galecki, A. T., Gao, C., Jalal, D., Perkins, B. A., Pop-Busui, R., Rossing, P., et al. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0381-0 · Cited by 138
Type 2 diabetes and bone fractures
Moseley, K. F. (2012) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328350a6e1 · Cited by 136 · cited 11×
“Anemia and bone and mineral metabolism disorders often develop earlier in DKD than in other types of CKD. Predominant tubulointerstitial disease is associated with damage to the peritubular interstitial cells that produce erythropoietin.”
InfluentialRedefining Blood-Pressure Targets — SPRINT Starts the Marathon
Perkovic, V., & Rodgers, A. (2015) · New England Journal of Medicine · doi:10.1056/nejme1513301 · Cited by 135
Renal Lesions Predict Progression of Diabetic Nephropathy in Type 1 Diabetes
Caramori, M. L., Parks, A., & Mauer, M. S. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070739 · Cited by 118
Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions
Saito, Y., Kida, H., Takeda, S.-C., Yoshimura, M., Yokoyama, H., Koshino, Y., & Hattori, N. (1988) · Kidney International · doi:10.1038/ki.1988.193 · Cited by 117 · cited 1×
“Segmental mesangiolysis is observed with progression of diabetes and thought to be associated with development of Kimmelstiel–Wilson nodules and microaneurysms, which often present together (29,30) (Figure 3).”
The impact of hyperfiltration on the diabetic kidney
Premaratne, E., Verma, S. K., Ekinci, E. I., Theverkalam, G., Jerums, G., & MacIsaac, R. J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.003 · Cited by 111 · cited 2×
“Overall, it is observed in 10%–40% or up to 75% of patients with DM1 and up to 40% of patients with DM2 (48).”
Back to the future: glomerular hyperfiltration and the diabetic kidney
Tuttle, K. R. (2017) · Diabetes · doi:10.2337/dbi16-0056 · Cited by 108 · cited 2×
“The overall effect is high intraglomerular pressure and glomerular hyperfiltration (47,49) (Figure 7).”
Self-citationAnaemia in diabetes: is there a rationale to TREAT?
Thomas, M. C., Cooper, M. E., Rossing, K., & Parving, H. ‐. (2006) · Diabetologia · doi:10.1007/s00125-006-0215-6 · Cited by 105
Foley, R. N., & Hakim, R. M. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009030282 · Cited by 100
Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule
Stout, L. C., Kumar, S., & Whorton, E. B. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90066-p · Cited by 90
The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis
Grabias, B. M., & Konstantopoulos, K. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00503.2013 · Cited by 74 · cited 2×
“The overall effect is high intraglomerular pressure and glomerular hyperfiltration (47,49) (Figure 7).”
The Kidney in Diabetes: Dynamic Pathways of Injury and Repair
Alexander, W., & Fioretto, P. (2007) · MD Conference Express · doi:10.1177/155989770700700616 · Cited by 66
Bullock, A., Burrows, N. R., Narva, A. S., Sheff, K., Hora, I., Lekiachvili, A., Cain, H., & Espey, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6601e1 · Cited by 64
Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes
Tuttle, K. R., Puhlman, M. E., Cooney, S. K., & Short, R. A. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00155.2001 · Cited by 51
Self-citationThe discovery of diabetic nephropathy: from small print to centre stage
Cameron, J. S. (2006) · Journal of Nephrology · doi:10.1093/joneph/19.s10.s75 · Cited by 49
Renal structures in type 2 diabetic patients with elevated albumin excretion rate
Østerby, R., TAPIA, J., Nyberg, G., Tencer, J., Willner, J., Rippe, B., & Torffvit, O. (2001) · Apmis · doi:10.1034/j.1600-0463.2001.d01-142.x · Cited by 46
Pacilli, A., Viazzi, F. C., Fioretto, P., Giorda, C. B., Ceriello, A., Genovese, S., Russo, G. T., Guida, P., Pontremoli, R., Cosmo, S. D., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2873 · Cited by 44
Tuttle, K. R., & Bruton, J. L. (1992) · Kidney International · doi:10.1038/ki.1992.274 · Cited by 42
Self-citationSaxena, S., Tyagi, I., Agrawal, U., Amitabh, V., & Jain, A. (2008) · Indian Journal of Nephrology · doi:10.4103/0971-4065.42336 · Cited by 40 · cited 1×
“It is paralleled by capillary and tubular basement membrane thickening (14,25,26) (Figure 1).”
Ck, L. (1995) · PubMed · Cited by 12
A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists
Rocco, M. V., & Cheung, A. K. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.024 · Cited by 7
Research works printed but not linked: 3
- 2016, Standards of medical care in diabetes-2016: Summary of revisions, Diabetes Care, 39, S4
- 87. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) NCT02065791, 2017. Available at: ClinicalTrials.gov. Accessed April 27, 2017. Articles from Clinical Journal of the American Society of Nephrology : CJASN are provided here courtesy of American Society of Nephrology
- Bakris, 2015, Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial, JAMA, 314, 884, 10.1001/jama.2015.10081 · DOI · Paper page
Cited by
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00519-5 · Cited by 1,461
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
“Although the true prevalence of nondiabetic kidney disease in diabetic individuals may be <10% [129], this possibility should always be considered and a kidney biopsy must be performed in the presence of certain clinical criteria: (1) short-duration type 1 diabetes, (2) diagnosis of autoimmune disease, (3) mild or abs…”
BackgroundMetabolomics: A New Tool to Reveal the Nature of Diabetic Kidney Disease
Huang, G., Li, M., Li, Y., & Mao, Y. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac041 · Cited by 922
Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893
Metadata
- Authors
- Alicic, R. Z., Rooney, M. T., & Tuttle, K. R.
- Affiliations
- University of Washington (US)
- Providence Health Care, Spokane, Washington;
- Corresponding author
- Alicic, Radica Z.
- Rooney, Michele T.
- Tuttle, Katherine R.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-05-18
- Volume
- 12
- Issue
- 12
- Pages
- 2032-2045
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5718284
- OpenAlex
- W2615714795
- Semantic Scholar
- 5221ad157f1f15727ba86e086ad7b5775982495f
- Cited by
- 2,898
- References
- 80
- Citations by year
- 2026: 430 · 2025: 412 · 2024: 442 · 2023: 458 · 2022: 424 · 2021: 337 · 2020: 246 · 2019: 107 · 2018: 32 · 2017: 8
- FWCI
- 96.16
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, chronic kidney disease, end-stage renal disease, glomerular hyperfiltration, albuminuria, glomerulosclerosis, tubulointerstitial fibrosis, cardiovascular mortality, biomarkers, therapeutic target, disease progression, best practice implementation
- MeSH terms
- Diabetic Nephropathies, Glomerular Filtration Rate, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Kidney Failure, Chronic, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.